文献速递中医内科中药与中成药合理使用

银黄清肺胶囊来源薯蓣皂苷元及其优化纳米偶联物靶向STAT3抗肺纤维化

Yin-Huang-Qing-Fei-Capsule derived diosgenin and its optimized nanoconjugate target STAT3 against pulmonary fibrosis.
PubMed 文献 · Phytomedicine · 2026-07-10

本研究以博来霉素诱导的小鼠肺纤维化模型验证银黄清肺胶囊的抗纤维化作用,通过LC-MS/MS与机器学习筛选出核心活性成分薯蓣皂苷元,并利用孟德尔随机化、分子对接、分子动力学模拟、表面等离子共振及siRNA实验验证STAT3为其直接功能靶点。进一步设计薯蓣皂苷元-二甲双胍纳米偶联物(DM),在体内显示出显著增强的抗肺纤维化疗效,为中药现代化提供了可复制的策略。

要点

  • 银黄清肺胶囊可显著缓解博来霉素诱导的小鼠肺纤维化。
  • 薯蓣皂苷元是银黄清肺胶囊抗肺纤维化的核心活性成分,STAT3为其直接功能靶点。
  • 薯蓣皂苷元-二甲双胍纳米偶联物(DM)在体内抗肺纤维化疗效显著增强。

核心结论

  • 薯蓣皂苷元-STAT3轴是银黄清肺胶囊抗肺纤维化的核心机制。
  • 薯蓣皂苷元-二甲双胍纳米偶联物(DM)具有增强的体内抗肺纤维化疗效和转化潜力。

研究设计与样本

  • 随机对照的临床前体内研究,结合体外药理验证、转录组分析、机器学习成分筛选和遗传因果推断。
  • 在博来霉素诱导的小鼠肺纤维化模型中验证银黄清肺胶囊的抗肺纤维化疗效。

主要发现

  • 银黄清肺胶囊显著减轻博来霉素诱导的小鼠肺纤维化。
  • 薯蓣皂苷元被鉴定为银黄清肺胶囊的核心抗肺纤维化成分,STAT3被验证为其直接功能靶点。
  • 薯蓣皂苷元以STAT3依赖的方式发挥抗纤维化作用,DM纳米胶束在体内抗肺纤维化疗效显著增强。

临床怎么用

  • 银黄清肺胶囊的抗肺纤维化作用可能通过薯蓣皂苷元靶向STAT3实现。
  • 薯蓣皂苷元-二甲双胍纳米偶联物(DM)作为优化纳米药物,具有提高转化潜力的可能。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pulmonary fibrosis (PF) is a progressive, fatal interstitial lung disease with limited curative therapeutic options. Yin-Huang-Qing-Fei (YHQF) capsule is an approved clinical Chinese patent medicine with emerging preclinical evidence of potential anti-fibrotic bioactivity, yet its core anti-PF constituents, direct functional targets, and the druggability of its key active monomer remain largely uncharacterized. PURPOSE: This study aimed to decipher the anti-PF pharmacodynamic basis of YHQF, validate its core active constituent and functional target, and optimize the druggability of the candidate monomer. STUDY DESIGN: A randomized, controlled preclinical in vivo study was conducted, coupled with in vitro pharmacological validation, transcriptomic profiling, machine learning-based constituent screening, and genetic causal inference for target prioritization. METHODS: The anti-PF efficacy of YHQF was verified in bleomycin (BLM)-induced mouse PF models. Core bioactive constituents were screened via LC-MS/MS and machine learning. Mendelian randomization (MR) was used for target prioritization, followed by molecular docking, molecular dynamics simulation, surface plasmon resonance (SPR) and siRNA assays for multi-dimensional target validation. Transcriptomic profiling was conducted to elucidate the STAT3-associated downstream regulatory pathways. A diosgenin-metformin nanoconjugate (DM) was rationally designed for druggability optimization. RESULTS: YHQF significantly alleviated BLM-induced PF in mice. Diosgenin was identified as YHQF's core anti-PF constituent, with STAT3 validated as its direct functional target. Diosgenin exerted STAT3-dependent anti-fibrotic effects, and DM nanomicelles exhibited notably enhanced in vivo anti-PF efficacy. CONCLUSION: This study defined the diosgenin-STAT3 axis as the core mechanism mediating YHQF's anti-PF effect, develops an optimized nanomedicine with improved translational potential, and provides a practical, replicable strategy for traditional Chinese medicine modernization.

来源:Phytomedicine,查看原文。版权归原作者所有。

引用

  1. Xu W, Xin G, Dong Y, et al. Yin-Huang-Qing-Fei-Capsule derived diosgenin and its optimized nanoconjugate target STAT3 against pulmonary fibrosis. Phytomedicine. 2026. PMID: 42497519. doi:10.1016/j.phymed.2026.158568

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。